Welcome to our dedicated page for Actinium Pharmac news (Ticker: ATNM), a resource for investors and traders seeking the latest updates and insights on Actinium Pharmac stock.
The Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) news page on Stock Titan aggregates company announcements, scientific conference updates and regulatory disclosures related to its Actinium-225 targeted radiotherapy programs. Actinium regularly issues press releases detailing preclinical and clinical data, corporate events and participation in oncology meetings, offering investors and observers insight into the evolution of its pipeline.
Recent news has focused heavily on ATNM-400, the company’s first-in-class, multi-indication Ac-225 antibody radioconjugate. Actinium has reported preclinical data for ATNM-400 in metastatic castration-resistant prostate cancer, non-small cell lung cancer (NSCLC) and breast cancer, including models resistant to standard-of-care therapies such as enzalutamide, 177Lu-PSMA-617, osimertinib, tamoxifen and trastuzumab. Releases describe superior tumor growth inhibition versus several approved agents, durable tumor control, and synergistic effects when ATNM-400 is combined with ARPIs or EGFR inhibitors.
News items also cover Actimab-A, a CD33-targeting Ac-225 therapeutic for acute myeloid leukemia, including its planned pivotal Phase 2/3 trial and a Cooperative Research and Development Agreement with the National Cancer Institute. Additional updates describe Iomab-ACT and Iomab-B in conditioning for bone marrow transplant and cell or gene therapies, as well as Actinium’s broader research efforts in solid tumors.
Visitors to this page can review earnings‑independent scientific updates, conference abstracts and corporate communications that outline Actinium’s development strategy, preclinical results and governance milestones such as annual meeting outcomes. For anyone tracking ATNM as an oncology development story, this news feed provides a centralized view of how the company portrays progress across its Ac‑225 radiotherapy platform.
Actinium Pharmaceuticals (NYSE: ATNM) reported positive survival data from its Actimab-A and CLAG-M combination trial for relapsed or refractory acute myeloid leukemia (AML) patients. Key findings include a 59% one-year overall survival for patients previously treated with Venetoclax, 75% measurable residual disease negativity, and a manageable safety profile. Notably, patients with a TP53 mutation showed a 52% one-year overall survival. These results were shared at the 64th Annual ASH Meeting, emphasizing the potential of Actimab-A as a treatment for high-risk AML patients previously deemed difficult to treat.
Actinium Pharmaceuticals (NYSE AMERICAN: ATNM) has announced a collaboration with Columbia University to study Actimab-A, a targeted radiotherapy for acute myeloid leukemia (AML). The partnership focuses on the use of gene-edited hematopoietic stem cells (eHSCs) to eliminate residual leukemia cells post-transplant. Preliminary results show promising data: 53% one-year and 32% two-year overall survival rates, with a 67% overall response rate and 72% measurable residual disease negativity in patients. The findings will be presented at the American Society of Hematology Annual Meeting on December 10, 2022.
Actinium Pharmaceuticals (ATNM) showcased promising results from its Phase 1 trial of Actimab-A combined with CLAG-M in treating relapsed or refractory acute myeloid leukemia (AML). Highlights include a median overall survival of 12 months, with 1-year and 2-year survival rates at 53% and 32%, respectively—significantly higher than existing treatments. The trial involved patients with adverse cytogenetics, including TP53 mutations. Data will be presented at the ASH Annual Meeting on December 10, 2022, enhancing the potential for Actimab-A's use as a backbone therapy in AML.
Actinium Pharmaceuticals has appointed Caroline Yarbrough as Chief Commercial Officer to lead the commercialization of Iomab-B. Previously with Novartis, Caroline has extensive experience in oncology and managing billion-dollar portfolios. CEO Sandesh Seth emphasized her expertise in launching cancer therapies and her role in expanding access to bone marrow transplants for elderly patients with acute myeloid leukemia. The company aims to file a Biologics License Application for Iomab-B, which recently showed significant efficacy in a pivotal Phase 3 trial.
Actinium Pharmaceuticals, Inc. (NYSE: ATNM) announced positive results from its pivotal Phase 3 SIERRA trial of Iomab-B for treating elderly patients with active relapsed or refractory acute myeloid leukemia (AML). The trial met its primary endpoint, achieving a durable complete remission (dCR) of 6 months post-treatment, with a p-value of <0.0001. Iomab-B demonstrated significant potential to increase patient access to bone marrow transplants (BMT) and improve patient outcomes, prompting the company to advance its Biologics License Application (BLA) submission to the FDA.
Actinium Pharmaceuticals, Inc. (NYSE: ATNM) announced a senior-level expansion of its clinical organization, strengthening its expertise in bone marrow transplant and acute myeloid leukemia. Key hires include Madhuri Vusirikala, MD, Akash Nahar, MD, Patrik Brodin, Ph.D., and Elaina Haeuber, enhancing the company's operational capabilities for pivotal programs Iomab-B and Actimab-A. Topline data from the Phase 3 SIERRA trial for Iomab-B is expected in Q4 2022. This expansion aims to advance clinical development and improve patient outcomes in hematological malignancies.
Actinium Pharmaceuticals, Inc. (NYSE: ATNM) will participate in the virtual Bio-Europe conference from November 2-4, 2022. The event is the largest biopharma partnering meeting in Europe, featuring over 4,000 attendees and 27,000 scheduled 1-on-1 meetings. Actinium's business development team will conduct individual meetings, which can be requested through the partneringONE® system. The company focuses on targeted radiotherapies for cancer treatment, with key products including I-131 apamistamab (Iomab-B) and Actimab-A, both undergoing clinical trials.
Actinium Pharmaceuticals (NYSE AMERICAN: ATNM) has appointed several key executives to strengthen its leadership team. Jenny Hsieh joins as Chief Strategy Officer, having previously led corporate strategy at Immunomedics. Sunitha Lakshminarayanan takes on the role of Senior Vice President, Head of CMC and Product Development, bringing extensive experience from Bristol Myers Squibb. Stephen Dressel is appointed Vice President of Strategic Finance and Analysis, with a background in finance at Regeneron. These additions come as the company prepares for pivotal clinical data results from the Iomab-B SIERRA trial and Actimab-A CLAG-M combination trial.
Actinium Pharmaceuticals (NYSE AMERICAN: ATNM) announced its participation at the Cantor Fitzgerald Oncology, Hematology & HemOnc Conference on September 28, 2022. Chief Medical Officer Dr. Avinash Desai will join a panel discussing "Addressing Challenges in Cell Therapy and Transplant" at 9:00 AM ET. The conference will be held at the Lotte New York Palace Hotel, where Actinium's executive team will also be available for one-on-one meetings. The company is focused on developing targeted radiotherapies to improve cancer treatment outcomes.
Actinium Pharmaceuticals (NYSE: ATNM) provided a corporate update on September 21, 2022, highlighting key upcoming milestones in its clinical pipeline. Key data releases expected include topline results from the pivotal Phase 3 SIERRA trial for Iomab-B and overall survival data from the Actimab-A CLAG-M combination trial, both anticipated in Q4 2022. The company reported approximately $116 million in cash and equivalents as of Q2 2022, sufficient to support operations through mid-2025, facilitating its commitment to advancing targeted radiotherapies for patients with high unmet medical needs.